Although the prevalence of smoking has declined among U.S. adults, smoking remains the leading preventable cause of cancer incidence and mortality. Quitting smoking increases life expectancy, and quitting at an earlier age is associated with more years of life gained. Effective pharmacotherapies to aid cessation are available, and the combination of behavioral support with pharmacotherapy optimizes cessation outcomes. Varenicline is an effective, first-line smoking cessation treatment, and recent research has investigated combination pharmacotherapy to improve the modest quit rates observed with monotherapy. The findings of two meta-analyses have indicated that varenicline combined with the nicotine patch was more effective than varenicline alone for smoking cessation However, no published studies to date have evaluated the combined impact of varenicline and oral nicotine replacement therapy (NRT) on smoking cessation in a randomized trial. Oral NRT, such as nicotine lozenges, can provide acute relief from cravings/withdrawal, and offers individuals the flexibility to deliver nicotine quickly, in contrast with the continuous, passive, and slow-acting delivery of the nicotine patch. Nevertheless, in clinical trials of other combination pharmacotherapies, participants' adherence to of oral NRT has been suboptimal, making it difficult to determine whether there is an added benefit. Given the near-ubiquity of smartphone ownership (85% of U.S. adults), it is plausible that smartphone-based medication adherence interventions could have a positive influence on pharmacotherapy adherence and smoking cessation. This investigative team has demonstrated the feasibility and potential efficacy of using combination varenicline plus oral NRT treatment to promote smoking cessation in a pilot factorial randomized trial. Likewise, pilot findings showed that medication adherence and smoking cessation rates were higher among those who received smartphone-based medication reminders than those who did not. The proposed study will enroll 496 adults who smoke cigarettes daily. The study will employ a 2x2 factorial design in which participants will be randomized to one of four combinations of two treatment factors: 1) pharmacological treatment (varenicline + nicotine lozenges vs. varenicline alone) and 2) smartphone medication adherence intervention (smartphone-based smoking cessation app with vs. without adherence components). The primary study outcomes will be biochemically-confirmed 7-day point prevalence abstinence at 26 weeks after a scheduled quit date, and medication adherence over the 13-week treatment period. Smartphone-based daily diaries will be employed to assess daily smoking and medication adherence. Notably, the proposed study will employ entirely remote assessment and treatment delivery strategies. Exploratory analyses will evaluate the potential interaction between medication type and the smartphone adherence intervention, and compare the influences of pharmacological treatment type and the medication adherence intervention on weekly physical symptoms (e.g., withdrawal, medication side effects). The overarching goal of the proposed research is to improve smoking cessation treatment and decrease cancer risk.

Start Date05 Jan 2026

Sponsor / Collaborator

University of Oklahoma

[+4]

NCT06811038

/ Not yet recruitingPhase 3IIT

Providing Nicotine Replacement Therapy to Enhance the Efficacy of a Smoking Cessation Smartphone App for Hispanic Adults

This phase III trial compares a smartphone application with or without nicotine replacement therapy in improving smoking cessation among Hispanic adults who would like to quit smoking. The iCanQuit smartphone application focuses on skills for managing urges, motivation, and relapse prevention with personalized quit plans. Nicotine replacement therapy works by giving small, steady doses of nicotine to help stop cravings and relieve symptoms that occur when a person is trying to quit smoking without any of the other harmful chemicals found in tobacco products.

Start Date01 Jan 2026

Sponsor / Collaborator

Fred Hutchinson Cancer Research Center

[+1]

NCT07220356

/ RecruitingPhase 4IIT

C-Raven: Pilot RCT of an Avatar-delivered Computerized Intervention for Tobacco Cessation With Community Health Worker Linkage to Lung Cancer Screening in Baltimore City (FY26)

In a residency clinic in Baltimore, the investigators propose to conduct a pilot RCT comparing a) an avatar-delivered computerized intervention (CI) for tobacco cessation augmented with CHW support and navigation to lung cancer screening to b) a waitlist control.
With a sample of participants from the residency clinic (N=30), the investigators will collect data on feasibility of recruitment, intervention engagement and completion, and short-term smoking cessation outcomes. Individuals will be assessed at baseline, 1 month, 3 months, and 6 months. The investigators will conduct interviews with a subset of pilot participants to collect qualitative data on intervention acceptability.

Start Date15 Dec 2025

Sponsor / Collaborator

The Johns Hopkins University

100 Clinical Results associated with Nicotine

100 Translational Medicine associated with Nicotine

100 Patents (Medical) associated with Nicotine

39,099

Literatures (Medical) associated with Nicotine

01 Mar 2026·Reproductive Biology

Moringa oleifera leaves aqueous extract mitigates nicotine-induced reproductive toxicity in male rats

Article

Author: Mahmoud, Aya A ; Dakrory, Ahmed Emam ; Omar, Amel Ramadan ; Ibrahim, Ahmed Mohamed

Nicotine, a chemical component included in tobacco, has been demonstrated to influence various facets of spermatogenesis and sperm functionality. Moringa oleifera Lam. (Moringaceae) is used in traditional medicine to treat various ailments, including reproductive toxicity. The current study aims to investigate the ameliorative effect of Moringa oleifera leaves aqueous extract (MOE) on nicotine (NT)-induced reproductive toxicity in male rats. Forty rats were assigned into four groups (n = 10): control (distilled water), MOE (400 mg/kg), NT (1 mg/kg), and NT + MOE groups, and orally treated for 56 days. At the end of the experiment, body and organ weights, epididymal sperm analysis, oxidative stress, hormone levels, and histopathological abnormalities were assessed. Nicotine administration results in a significant increase in malondialdehyde (MDA) levels, accompanied by a decrease in glutathione (GSH), catalase (CAT), and superoxide dismutase (SOD). Consequently, NT decreases sperm quality and serum reproductive hormone levels, including testosterone, follicle-stimulating hormone (FSH), and luteinizing hormone (LH), and distorts testicular tissue architecture. The oral administration of MOE caused a significant decrease in MDA concentration and an increase in the levels of antioxidant molecules (GSH, CAT, SOD) and serum reproductive hormones levels. Additionally, it improved sperm characteristics, including sperm count, motility, viability, and morphology and partial improvement to the histological architecture of the testis. Our findings imply that 400 mg/kg of Moringa oleifera leaves may be utilized to enhance reproductive parameters against NT-induced reproductive toxicity in male rats, with the primary mechanism attributed to its antioxidant properties.

01 Feb 2026·BEHAVIOURAL BRAIN RESEARCH

Nicotine-induced conditioned place preferences in humans

Article

Author: Astur, Robert S ; Burrows, Christopher N ; Sklenarik, Skyler M

This study investigated whether a conditioned place preference (CPP) could be established for a virtual reality (VR) room paired with nicotine. Forty-four undergraduates with nicotine use completed a 3-day, within-subjects protocol. In session 1, participants were randomly assigned to receive either a 4 mg nicotine or placebo lozenge. They were then confined to one of two visually distinct VR rooms, in which they completed three conditioning sessions. In session 2, participants crossed over to the other condition (nicotine or placebo) and the alternate VR room, then completed three conditioning sessions. Session 3 was a test session in which no lozenge was given and participants had free access to both VR rooms. Participants displayed an explicit CPP by rating the nicotine-paired room significantly more enjoyable and choosing the nicotine-paired room over the placebo-paired room in a forced-choice test of room preference. Interestingly, participants did not display an implicit CPP for the nicotine-paired room during the test session. However, greater e-cigarette dependence was positively correlated with implicit CPP for the nicotine-paired room, indicating that individuals with higher nicotine dependence spent longer in the nicotine-paired room during the test session. Intriguingly, sex differences emerged: females demonstrated implicit CPP (time spent in the nicotine-paired room), whereas males showed explicit CPP (self-reported enjoyment of and preference for the nicotine-paired room). These findings are the first demonstration that humans exhibit CPP for a nicotine-paired context and highlight the potential of the VR-CPP to reveal meaningful individual and biological differences in nicotine reward and addiction science.

01 Jan 2026·BIORESOURCE TECHNOLOGY

Study on the pyrolysis interactions of different anatomical parts of flue-cured tobacco stalks and the catalytic cracking characteristics of nicotine

Article

Author: Nie, Hanwen ; Chen, Zhenguo ; Gong, Xun ; Sun, Guangwei ; Zhang, Jinming ; Lin, Luqiu

The pyrolysis of flue-cured tobacco stalks (TS) faces challenges such as low bio-oil value and utilization efficiency. Existing studies have overlooked the anatomical heterogeneity of tobacco stalks, thereby limiting the directional regulation of high-value components, such as nicotine and phenolic compounds. This study divides TS into the husk (TSH), xylem (TSX), and pith (TSP), and investigates their physicochemical properties, pyrolysis behavior (through TGA and fixed-bed pyrolysis experiments), and interactions. Additionally, DFT calculations are used to elucidate the catalytic mechanism of K⁺/H⁺ on nicotine cracking. The main findings are as follows: (1) TSH contains the highest nicotine and KCl content, TSX accounts for 67.39 wt% of the dry weight of TS, and due to its high volatile content and low ash content, it has an advantage in bio-oil production, while TSP has a higher sugar content; (2) TSX dilutes the potassium concentration in TSH and TSP, reduces the catalytic effect of potassium, and delays small molecule cracking, shifting the maximum weight loss rate temperature from 308 °C to 338 °C; (3) GC-MS results show that nicotine yield peaks at 550 °C for TS, with nicotine yield higher than that of TSH. TSX has a higher phenolic yield, and K⁺ in TSH and TSP promotes the condensation of phenolics into biochar (XPS confirms an increase in sp² carbon); (4) DFT calculations demonstrate that the synergistic effect of K⁺/H⁺ lowers the C4-C7 bond dissociation energy of nicotine by 39 %, catalyzing nicotine cracking, and more pyridine derivatives are observed in the bio-oil.

203

News (Medical) associated with Nicotine

15 Nov 2025

·www.sciencedaily.com

Smoking cannabis with tobacco may disrupt the brain’s “bliss molecule”

Scientists found that people who use both cannabis and tobacco show a distinct brain pattern tied to mood and stress regulation. Their scans revealed higher levels of an enzyme that reduces a natural feel-good molecule in the brain. This imbalance may help explain why co-users experience more anxiety and struggle more when quitting.People who use both cannabis and tobacco show measurable differences in brain activity compared to those who rely solely on cannabis, according to new findings from a McGill University team at the Douglas Research Centre. These results may help clarify why people who combine the two substances more often experience symptoms such as anxiety and depression, and why attempts to quit cannabis tend to be more difficult for them than for people who avoid tobacco. "This is the first evidence in humans of a molecular mechanism that may underlie why people who use both cannabis and tobacco experience worse outcomes," said lead author Rachel Rabin, Associate Professor in McGill's Department of Psychiatry and researcher at the Douglas. "Identifying this mechanism is an important step toward finding targets for future medications to treat cannabis use disorder, especially among those that co-use tobacco. Right now, the only available treatments are behavioral therapies such as counseling," she said. Co-Use Common Even as Tobacco Use Declines In Canada, roughly one in 20 people who used cannabis within the past year are considered at risk for cannabis use disorder. Among people who consume cannabis more often, the rate jumps to about one in three. The researchers note that tobacco use is decreasing overall, yet the majority of cannabis users still report using tobacco as well. Rabin explained that most previous studies focused on each substance separately, leaving a major gap that this early-stage research is beginning to fill. Changes in the Brain's "Bliss Molecule" System PET scans showed that people who used both cannabis and tobacco had elevated levels of FAAH when compared to those using cannabis alone. FAAH is an enzyme that breaks down anandamide, a naturally occurring compound often described as the "bliss molecule" because of its influence on mood and stress responses. Higher FAAH levels mean lower anandamide levels, a pattern that has previously been linked to anxiety, depression and higher relapse rates among people trying to stop using cannabis. Small Study Offers Early Clues The analysis involved 13 young adults. Eight used only cannabis, while five used cannabis and smoked cigarettes every day. Cannabis use averaged slightly above one gram per day. Cigarette intake ranged from one to 12 per day. Because the data was originally gathered for an unrelated project, there was no tobacco-only group for comparison. This means the changes could potentially be caused by tobacco alone, although the researchers believe the results point to a more complex interaction. "What surprised us was how strong the effect was, and how different it was from those who only used cannabis, compared to those who used both tobacco and cannabis," said co-author Romina Mizrahi, Professor of Psychiatry and director of the McGill Research Center for Cannabis. Next Steps in Understanding Tobacco's Role The team is now recruiting people who smoke cigarettes and people who vape nicotine for a follow-up project that will explore whether similar brain changes appear in the absence of cannabis. "A preliminary investigation of tobacco co-use on endocannabinoid activity in people with cannabis use" by Rachel Rabin, Joseph Farrugia, Ranjini Garani and Romina Mizrahi was published in Drug and Alcohol Dependence Reports. The study received funding from the National Institute of Mental Health.

03 Nov 2025

·www.prnewswire.com

Groundbreaking Study Reveals Text Message Vaping Cessation Program Also Helps Young People Quit Cannabis

First study to demonstrate that interventions to help quit vaping nicotine can simultaneously reduce cannabis use among adolescents and young adults WASHINGTON, Nov. 3, 2025 /PRNewswire/ -- A new study published in Substance Abuse Treatment, Prevention, and Policy today from Truth Initiative — the nation's largest public health nonprofit dedicated to preventing youth and young adult nicotine addiction and empowering quitting for all — reveals that its text message vaping cessation program not only helps young people quit nicotine but also significantly reduces cannabis use. This groundbreaking research, published as secondary analyses from two large randomized controlled trials, demonstrates the potential for a "spillover" effect where targeting one substance can lead to beneficial changes in the use of other substances. The study also documented concerning prevalence rates of cannabis use among young people seeking vaping cessation support. The text message intervention is part of EX Program, a free digital cessation resource from Truth Initiative developed in collaboration with Mayo Clinic. EX Program is tailored to meet the unique challenges faced by young people looking to break free from nicotine addiction. It offers evidence-based tools designed to support quitting through personalized quit plans, interactive text messages, and 24/7 access to the nation's most established online quit community. EX Program, previously known as This is Quitting, has been proven effective in the first randomized clinical trials of nicotine vaping cessation amongadolescents andyoung adults, and has helped millions on their journey to quit nicotine over nearly two decades. Building on EX Program's proven success in helping young people quit nicotine, this new research addresses a critical gap in the scientific literature. Few studies have examined concurrent nicotine and cannabis cessation, and no clinical practice guidelines exist for treating co-use among young people. These findings reveal that young people who received the interactive text message intervention were significantly more likely to achieve "dual abstinence" from both nicotine e-cigarettes and cannabis at seven months compared to those in the control group, even though the intervention did not specifically address cannabis. Among adolescents, 38.5% of those receiving the text message intervention achieved dual abstinence from both nicotine e-cigarettes and cannabis compared to 25.0% in the control group — a 13.5% advantage. Among young adults, 17.9% of intervention participants achieved dual abstinence versus 13.3% in the control group, a 4.6% difference. The study also found that 74.6% of adolescents and 59.2% of young adults reported past 30-day cannabis use at baseline — rates far exceeding national averages from population-based surveys. These are troubling trends given that youth cannabis use negatively impacts brain development and shows worrying links to depression and earlier onset and worse symptoms of psychotic illness in those who are susceptible. Young people who use nicotine and cannabis are exposed to negative health effects of both substances – nicotine is highly addictive and can also negatively impact developing brains – warranting continued surveillance of youth cannabis use. "These findings reveal a powerful ripple effect: when we help young people quit vaping nicotine, we're often helping them reduce their cannabis use at the same time, even without explicitly targeting cannabis," said Dr. Amanda Graham, Chief Health Officer at Truth Initiative and lead author of the study. "This research suggests that substance use interventions may have broader benefits than we previously understood, potentially offering a more efficient approach to addressing the complex patterns of polysubstance use we see among young people today." Age-related differences in treatment response were also uncovered: while adolescents had higher baseline cannabis use rates, they showed substantially greater reductions in cannabis use and higher dual abstinence rates compared to young adults, suggesting that younger populations may be more responsive to cessation interventions. The researchers suggested several potential mechanisms for these spillover effects, including the shared use of similar vaping devices for both nicotine and cannabis, common behavioral triggers and contexts, and the application of general behavior change skills across different substances. "The high rates of cannabis use we observed among young people seeking vaping cessation support -- nearly three-quarters of adolescents and six in ten young adults -- highlight that this population faces complex, interconnected substance use challenges," Graham added. "While it's encouraging that our nicotine-focused intervention had beneficial effects on cannabis use, these findings also underscore the need for future research to better understand how best to help young people who use multiple substances." The research was conducted using data from two randomized controlled trials funded by Truth Initiative, with additional support from CVS Health Foundation for non-personnel expenses in the young adult trial. For more information about Truth Initiative, please visit truthinitiative.org. For more information about EX Program, please visit truthinitiative.org/exprogram. Teens and young adults can text EXPROGRAM to 88709 to receive free quit vaping support. Background Both clinical trials were conducted by Truth Initiative with oversight from Advarra Institutional Review Board. The adolescent trial (n=1,503) was conducted from October 2021 to October 2023, while the young adult trial (n=2,588) was conducted from December 2019 to November 2020. Participants were recruited via social media advertisements and randomized to receive either the interactive text message intervention or assessment-only control messages. All branding was removed to eliminate potential bias and ensure participant blinding. About Truth Initiative Truth Initiative® is a national nonprofit public health organization committed to a future free from lifelong addiction, fostering healthier lives and a more resilient nation. Our mission is to prevent youth and young adult nicotine addiction and empower quitting for all. Through our evidence-based, market-leading cessation intervention, EX® Program, and national public education campaigns, we lead the fight against youth and young adult tobacco use. Learn more at truthinitiative.org. About EX Program EX® Program is a proven-effective tobacco cessation program, developed by Truth Initiative® with Mayo Clinic, that brings together the best evidence-based quitting approaches, interactive digital quitting programs, and the most established online quit community. EX Program has helped millions of youth and adults develop the skills and confidence to successfully quit. Truth Initiative research has shown that EX Program text messages can increase a user's odds of quitting by up to 40%. To learn more, visit exprogram.com. SOURCE Truth Initiative 21% more press release views with Request a Demo

Clinical ResultClinical Study

29 Oct 2025

·www.einpresswire.com

Trinidad and Tobago Poised to Lead the Caribbean in Evidence-Based Public Health Innovation Ahead of COP11

PORT OF SPAIN, TRINIDAD AND TOBAGO, October 29, 2025 / EINPresswire.com / -- Happening from November 17th to November 22nd, the Eleventh Session of the Conference of the Parties (COP11) to the WHO Framework Convention on Tobacco Control (WHO FCTC) is around the corner, and Trinidad and Tobago has an unprecedented opportunity to embrace innovation and lead the Caribbean in advancing public health. Recognizing this potential, the We Are Innovation global network organized a conference in Port of Spain to highlight the importance of science-based and innovation-oriented policies for creating healthier societies. The event, titled “Innovation Pathways: T&T Leadership for a Smoke-Free Future,” gathered advocates, experts, and public officials to explore how evidence-based innovation can accelerate progress toward better health outcomes. The first expert to speak was Ingid Dragan Taricano (BRA), a distinguished toxicologist and pharmacologist with over four decades of expertise in drug safety and regulatory science. Taricano shared insights on “Harm Reduction: Toxicology Review,” presenting information on the toxicological composition of various risk-related behaviors and their impacts on the human body. She also explained the particularities of certain naturally occurring compounds that have been misunderstood in public discourse, highlighting their biological properties and potential therapeutic applications for diseases like Parkinson's and Ulcerative Colitis . According to Taricano: “Nicotine is not a demon. A big misconception surrounding it is the idea that it causes cancer. It is wrong - nicotine is an addictive molecule, but not an oncogenic one. The problem is the tar. Considering the composing substances and the way nicotine is absorbed, INPs appear as a safer option to combustion cigarettes. The regulation needs to access this, allowing smokers to switch. It is toxicology - and it is very important to establish rules.” The second speech, “COP11 and the Silenced Voices: Why Regulators Must Listen to Consumers in Health Policy,” was delivered by Miguel Okumura (BRA), an electrical engineer, president of THR Brazil, and vice-president of ARDT Iberoamérica. Okumura shared his journey as someone who successfully changed his habits through innovation and as an advocate who has been silenced many times. He also examined the effects of restrictive health policies that, instead of reducing harm, have contributed to unregulated practices. Okumura commented: “I smoked for around 7 years and quit completely. My case could be considered a public health success if I was born in the UK or Sweden instead of Brazil. Silence does not lead to good policies, dialogue does. It is necessary to create formal channels, differentiate stakeholders and use consumers as real-world data. The consumer voice is not the problem - it is the compass to the solution.” The final intervention came from Federico N. Fernández (ARG), We Are Innovation’s CEO, who spoke on “Saving Lives Through Innovation and Caribbean Leadership.” Fernández presented Trinidad’s health data, noting its stagnation, and showcased real-life success stories of countries that saw major progress after implementing innovation-oriented public health policies. Fernández shared: "Trinidad and Tobago has a historic opportunity at COP11 to lead the Caribbean toward evidence-based tobacco policy. While the smoking rate remains stuck at 19 percent, countries embracing innovation - like Sweden, the UK, and Japan - have seen dramatic reductions. With Saint Kitts and Nevis and Guyana already advocating for harm reduction, Trinidad and Tobago can build on this Caribbean momentum. At COP11, Trinidad and Tobago can show the region that we choose evidence over ideology and outcomes over outdated approaches.” The event was moderated by Tetiana Rak (UKR), We Are Innovation’s COO, and concluded with a Q&A session for the audience. Trinidad and Tobago’s smoking rate is 19 percent, with smoking-related illnesses responsible for 5.4 percent of deaths every year. That, however, can change. By adopting a regulatory framework that guarantees the accessibility, affordability, and acceptability of innovative public health solutions, the country can significantly reduce its smoking rates and accelerate its journey toward becoming a smoke-free society. The choice is clear: maintain current policies and accept stagnation, or embrace innovation and evidence-based policymaking to improve public health nationally and regionally. ENDS ABOUT WE ARE INNOVATION We Are Innovation is a network encompassing over 50 think tanks, foundations, and NGOs, representing the diverse voices of a global civil society committed to advancing human creativity, embracing new technologies, and promoting innovative solutions. Learn more at https://weareinnovation.global/ Beatriz Santos We Are Innovation email us here Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

100 Deals associated with Nicotine

External Link

KEGG	Wiki	ATC	Drug Bank
D03365	Nicotine	N07BA01	DB00184

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Smoking Cessation	South Korea	SAEHAN PHARM	28 Aug 2007
Tobacco Use Disorder	Australia	Johnson & Johnson Pacific Pty Ltd.	27 Nov 2001
Nicotine Dependence	United States	Haleon US Capital LLC	13 Jan 1984

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acral Lentiginous Malignant Melanoma	Phase 3	United States	McNeil AB	01 Mar 2011
Dyskinesia, Drug-Induced	Phase 2	United States	Neuraltus Pharmaceuticals, Inc.	01 Oct 2009
Parkinson Disease	Phase 2	United States	Neuraltus Pharmaceuticals, Inc.	01 Oct 2009
Lung Cancer	Phase 1	United States	Pfizer Inc.	16 Jun 2017
disorder of aging	Preclinical	China	The Shenzhen Institutes of Advanced Technology	07 Feb 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06289192 (CTgov)	Phase 4	Lung Cancer \| Tobacco Use Disorder	5	Lung Cancer Screening+Nicotine Replacement Product	gxcwmvbimn = xazwzvagrq xmcfsnbotq (pctdfdevbj, ekwalxaevc - rlwpqqcjun) View more	-	10 Sep 2025
NCT04038255 (CTgov)	Phase 4	Neoplasms	20	Self-help smoking cessation materials+Nicoderm (Usual Care)	cwlgvtbxih = seqzcvuooj qyobapjqkm (dqrmrebbfu, nrrzribzhp - culizqsjik) View more	-	09 Sep 2025
				Craving-to-Quit app+Nicoderm (Craving-to-Quit App)	cwlgvtbxih = ylcwpygytn qyobapjqkm (dqrmrebbfu, zckhfxgiri - oomgztvujc) View more
NCT04590404 (CTgov)	Phase 3	Smoking	606	Metabolism Informed Smoking Treatment (Nicotine metabolite ratio (NMR)-based selection of pharmacotherapy)+Nicotine Replacement Therapy+Varenicline	jvbmgkkhwq = tmvgrvnlmm moannrxezs (sxqsexeirj, kxhhviwllr - zvewmmnvsp) View more	-	05 Jun 2025
NCT05030766 (CTgov)	Phase 4	Smoking Cessation \| HIV Infections \| Smoking	95	Nicotine replacement patches (Mindfulness Training (MT) and NRT (Phase 1))	mzhrlfybix = ppkculqeax evjxgbwxkq (qsbtpnybau, vgytifeksg - kugcfztuel) View more	-	04 Jun 2025
				Nicotine replacement patches+NRT (Contingency Management (CM) and NRT (Phase 1))	mzhrlfybix = ksuzufdrts evjxgbwxkq (qsbtpnybau, oqcrwxxqzq - eoeuibsefr) View more
NCT04946825 (CTgov)	Phase 2	Smoking Cessation \| Nicotine Dependence	396	Nicotine replacement therapy patch+Continue electronic cigarettes (Quit Cigarettes, But Continue Using E-cigarettes, With Nicotine Replacement Therapy and Text Support)	dqhsyleylz = outnxnslxv yahtrwfifu (kpxcohetal, lldvyvfznu - eekrvgvypr) View more	-	22 May 2025
				Nicotine replacement therapy patch+Quit electronic cigarettes (Quit Cigarettes and Quit E-cigarettes With Nicotine Replacement Therapy and Text Support.)	dqhsyleylz = aybnmfvygv yahtrwfifu (kpxcohetal, spjepnnsni - albfaplcby) View more
NCT02265874 (CTgov)	Phase 1/2	Sarcoidosis, Pulmonary	50	Habitrol (Treatment)	sembzxmall(crjtcicazf) = egalwlqder lmimvvszmw (ozauezosce, 0.22) View more	-	24 Apr 2025
				Placebo to Habitrol (Control)	sembzxmall(crjtcicazf) = uojvoivvzx lmimvvszmw (ozauezosce, 0.04) View more
NCT04994444 (CTgov)	Phase 2/3	Smoking Cessation	49	Nicoderm CQ (Preloading)	awufmdjvph(pseqzraiio) = kfuolinlyn drwmsaypus (zvsqlxuifn, 13.2) View more	-	06 Apr 2025
				Nicoderm CQ (Standard Treatment)	awufmdjvph(pseqzraiio) = xtqeaczvos drwmsaypus (zvsqlxuifn, 21.8) View more
NCT04433767 (Pubmed)	Phase 2	Depressive Disorder nicotine metabolite concentrations	29	Transdermal nicotine patches	yrdvikeamo(rbsneusera) = improvement in self-reported affective symptoms (apathy, insomnia, rumination, and generalized anxiety symptoms), negativity bias, and disability tcgpqjgcmk (hmxlqtbmvj ) View more	Positive	01 Oct 2024
NCT05253573 (SurvLaos, CTgov)	Phase 2	Neoplasms \| Smoking	80	Self-help materials (to support smoking cessation)+Nicotine patch (Automated Treatment)	tdrhzztmis = wcvocwerfk jbgjrmtsoo (cwebuzqvvd, frmdqhnwvc - cgcmebbnqa) View more	-	28 Aug 2024
				Self-help materials (to support smoking cessation)+Nicotine patch (Standard Care)	tdrhzztmis = jdlbsqjsru jbgjrmtsoo (cwebuzqvvd, oupxzrgdua - mqemoikmhh) View more
NCT03272685 (CTgov)	Phase 3	Nicotine Dependence	799	Very Low Nicotine Content Cigarettes (Very Low Nicotine Content Cigarettes)	ftwtbbefcf(jidlqaykyp) = pidwubetws ijiilrcylv (zzfttnzugp, 7.88) View more	-	20 Aug 2024
				Normal Nicotine Content Cigarettes (Normal Nicotine Content Cigarettes)	ftwtbbefcf(jidlqaykyp) = grjnjamtbo ijiilrcylv (zzfttnzugp, 9.07) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis